3,865 Shares in TransMedics Group, Inc. (NASDAQ:TMDX) Bought by Freestone Grove Partners LP

Freestone Grove Partners LP purchased a new stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 3,865 shares of the company's stock, valued at approximately $241,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Arizona State Retirement System increased its holdings in TransMedics Group by 1.9% during the 4th quarter. Arizona State Retirement System now owns 9,668 shares of the company's stock valued at $603,000 after acquiring an additional 184 shares in the last quarter. Envestnet Portfolio Solutions Inc. increased its position in TransMedics Group by 7.2% during the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 4,721 shares of the company's stock worth $294,000 after buying an additional 317 shares in the last quarter. Park Avenue Securities LLC lifted its holdings in TransMedics Group by 3.8% in the 4th quarter. Park Avenue Securities LLC now owns 8,797 shares of the company's stock valued at $548,000 after purchasing an additional 322 shares in the last quarter. Atlas Capital Advisors Inc. acquired a new stake in TransMedics Group during the fourth quarter worth approximately $31,000. Finally, Alliancebernstein L.P. grew its position in shares of TransMedics Group by 1.2% in the fourth quarter. Alliancebernstein L.P. now owns 40,572 shares of the company's stock valued at $2,530,000 after purchasing an additional 500 shares during the period. Institutional investors and hedge funds own 99.67% of the company's stock.

TransMedics Group Stock Up 2.7 %

Shares of NASDAQ:TMDX traded up $2.51 during midday trading on Wednesday, hitting $95.89. 951,486 shares of the stock were exchanged, compared to its average volume of 1,325,497. The business's fifty day simple moving average is $77.20 and its two-hundred day simple moving average is $76.01. TransMedics Group, Inc. has a 52-week low of $55.00 and a 52-week high of $177.37. The company has a market capitalization of $3.24 billion, a PE ratio of 102.01 and a beta of 1.91. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20.

Analyst Upgrades and Downgrades

TMDX has been the subject of several research reports. Piper Sandler reissued an "overweight" rating and set a $105.00 price objective (up from $90.00) on shares of TransMedics Group in a research note on Tuesday, April 29th. Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a research note on Wednesday, April 23rd. Finally, Canaccord Genuity Group restated a "buy" rating and issued a $104.00 price target on shares of TransMedics Group in a research report on Tuesday, March 11th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, TransMedics Group currently has an average rating of "Moderate Buy" and a consensus target price of $124.20.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.